Oral therapy of necrotizing enterocolitis
US9562066B2 · kind B2 · utility
2Cited by
28References
6Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 25, 2013 |
| Grant date | Feb 7, 2017 |
| Priority date | — |
| Expiry date | Oct 20, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of treating or reducing the risk of necrotizing enterocolitis (NEC) in an infant comprising orally administering an effective amount of a CpG-ODN. It is based, at least in part, on the results of experiments in which orally administered CpG-ODNs were observed to reduce the histopathology and markers of inflammation in a murine model for NEC. The present invention further provides for oral formulations of CpG-ODN for administration to infants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.